Diazyme Lipoprotein (a) Assay
Lipoprotein, Low-Density, Antigen, Antiserum, Control. 510(k) K180074, from Diazyme Laboratories, Inc. (Poway, CA). Product code DFC, class 2.
As of Nov 20, 2026, K180074 is an FDA 510(k) held by Diazyme Laboratories, Inc., substantially equivalent on Mar 22, 2018 after 71 days, with no recalls tied to it in FDA's recall database.
- Review time: 71 days
- Recalls: 0
- Cited as a predicate by: 2 devices
The Diazyme Lipoprotein (a) Assay is intended as a latex particle enhanced immunoturbidimetric assay for the in vitro quantitative determination of lipoprotein(a) [Lp(a)] concentration in human serum or plasma on Clinical Chemistry Systems.
- Lipoprotein (a) Molarity AssayK253069 · Diazyme Laboratories, Inc. · Jun 16, 2026
- Lp(a) UltraK211058 · SENTINEL CH. SpA · Dec 22, 2022
- Lipoprotein (a) Molarity AssayK253069 · Diazyme Laboratories, Inc. · Jun 16, 2026
- Tina-quant Lipoprotein(a) Gen.2 MolarityK241220 · Roche Diagnostics Operations · Jan 24, 2025
- Lp(a) UltraK211058 · SENTINEL CH. SpA · Dec 22, 2022
- Type
- Traditional
- Received
- Jan 10, 2018
- Review panel
- Immunology
- Regulation
- 21 CFR 866.5600
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files